Sanux Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 28-10-2024
- Paid Up Capital ₹ 0.50 M
as on 28-10-2024
- Company Age 3 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -44.70%
(FY 2023)
- Ebitda -52.43%
(FY 2023)
- Net Worth -82.62%
(FY 2023)
- Total Assets 3250.45%
(FY 2023)
About Sanux Laboratories
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Gandham Rao, Surya Vegesna, Venkata Vegesna, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24297AP2021PTC117649
- Company No.
117649
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2021
- Date of AGM
12 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sanux Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gandham Rao  | Managing Director | 11-Mar-2021 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Surya Vegesna | Director | 20-Mar-2024 | Current |
| Venkata Vegesna | Director | 11-Mar-2021 | Current |
| Rehana Shaik | Director | 11-Mar-2021 | Current |
| Vijaya Gandham | Director | 11-Mar-2021 | Current |
Financial Performance of Sanux Laboratories.
Sanux Laboratories Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 44.7% decrease in profit. The company's net worth observed a substantial decline by a decrease of 82.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanux Laboratories?
Unlock access to Sanux Laboratories's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sanux Laboratories?
Sanux Laboratories has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanux Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanux Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
